Pulmonx to report Q2 2026 financial results on July 29
Pulmonx Corporation will announce its Q2 2026 financial results on July 29, 2026, followed by a conference call at 1:30 p.m. PT. The company specializes in minimally invasive treatments for COPD, with products like the Zephyr Valve available in over 25 countries.
*this image is generated using AI for illustrative purposes only.
Pulmonx Corporation will release its financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. The company's management will host a conference call to discuss the financial results, beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website.
Conference Call Details
The conference call will provide an opportunity for investors and analysts to hear directly from Pulmonx's management regarding the company's financial performance for Q2 2026. Participants can access the live webcast or listen to the archived version later.
| Event | Date | Time (PT) | Time (ET) |
|---|---|---|---|
| Q2 2026 Financial Results Release | July 29, 2026 | After market close | After market close |
| Conference Call | July 29, 2026 | 1:30 p.m. | 4:30 p.m. |
About Pulmonx Corporation
Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company's products, including the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform, are designed to assess and treat patients with severe emphysema/COPD. The Zephyr Valve has received FDA pre-market approval and is commercially available in more than 25 countries.
What market trends or factors might influence Pulmonx's Q2 2026 financial performance?
How could the results impact investor sentiment and the company's stock price?
What strategic initiatives or product developments might Pulmonx highlight during the call?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
